Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2017

View Archived Issues

Bristol-Myers Squibb offers pipeline update of first quarter 2017

AstraZeneca updates regulatory and clinical progress of first quarter 2017

Vivet Therapeutics closes series A financing round

Lundbeck describes brain-penetrant PDE1 inhibitors for cognitive disorders

NIH grant supports Spero's preclinical development of SPR-720 for TB

FDA awards new designations to three Sangamo programs

Saniona participates in formation of Scandion Oncology

OncoMed initiates phase Ia study of OMP-313M32 in advanced solid tumors

FLX-787 demonstrates clinical benefit for treating nocturnal leg cramping

Celsion reports new data from OVATION study of GEN-1 in ovarian cancer

Polymorphism in TDP1 associated with poor survival in SCLC patients

Zafgen reports phase I topline data on ZGN-1061

ImMAGE Biotherapeutics begins repeat toxicology study for IMT-001

Galapagos identifies IRAK-4 inhibitors

Rhythm advances setmelanotide program into phase III for pro-opiomelanocortin deficiency obesity

Otsuka Pharmaceutical patents MAPK3 and MAPK1 inhibitors

Cardioxyl Pharmaceuticals divulges nitroxyl donors

ISIS-581088/AZD-5363 studies target the androgen receptor and AKT kinase in prostate cancer

Array BioPharma discovers FGFR tyrosine kinases inhibitors

Aplidin granted orphan drug designation in Switzerland for multiple myeloma

Shanghai Institute Materia Medica and Sunnylife Pharma patent BTK inhibitors

ADC Therapeutics enrolling patients in phase I trial of ADCT-502

Dauntless Pharmaceuticals reports promising phase I results for intranasal octreotide acetate

MDxHealth and Maastricht University expand research collaboration

Commense signs licensing agreement with UBC for microbiome-based therapy to prevent asthma

Compound shows promise in vivo for heart failure therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...